drugset / Trial / NCT05668741
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Phase 1/2
Active not recruiting
26 enrolled
Vertex Pharmaceuticals Incorporated
Moderna, Inc · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Timeline
- Start
- 2023-02-27
- Primary completion
- 2026-04-21
- Completion
- 2026-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VX-522 | Messenger RNA (mRNA) | — | Inhaled |
| Background | IVA | Unknown | — | Oral |